Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081731%3A_____%2F18%3A00494595" target="_blank" >RIV/68081731:_____/18:00494595 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1177/0271678X17714656" target="_blank" >http://dx.doi.org/10.1177/0271678X17714656</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/0271678X17714656" target="_blank" >10.1177/0271678X17714656</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma

Popis výsledku v původním jazyce

Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment. A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab. We show that vascular morphology was normalised over the time period investigated, but vascular function was not improved, resulting in poor tumoural blood flow and increased hypoxia.

Název v anglickém jazyce

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma

Popis výsledku anglicky

Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment. A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab. We show that vascular morphology was normalised over the time period investigated, but vascular function was not improved, resulting in poor tumoural blood flow and increased hypoxia.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/GA16-13830S" target="_blank" >GA16-13830S: Perfuzní zobrazování v magnetické rezonanci pomocí komprimovaného snímání</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Cerebral Blood Flow and Metabolism

ISSN

0271-678X

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

1741-1753

Kód UT WoS článku

000446200600007

EID výsledku v databázi Scopus

2-s2.0-85045044092